The Patent Finder

Sofar S.P.A.

4 patents currently held · Updated Nov 22, 2026
17 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Jul 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 4, 2027
    The maintenance fee for Composition for use in the treatment of intestinal alterations (US 11,690,889) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
  • 1 fee due May 24, 2027
    The maintenance fee for Derivatives of mesalazine, process of their preparation and their use in the treatment of intestinal inflammatory diseases (US 9,193,673) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 terms have ended since Aug 24, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 4 of 4

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,916,201Controlled-Release Granular Compositions Containing Mesalazine and Process for the Manufacture Thereof
In force
 · High confidence
In forceHigh confidence
US 9,193,673Derivatives of mesalazine, process of their preparation and their use in the treatment of intestinal inflammatory diseases
In force
 · USPTO record
In forceUSPTO record
US 10,881,703Composition for use in the treatment of intestinal alterations
In force
 · USPTO record
In forceUSPTO record
US 11,690,889Composition for use in the treatment of intestinal alterations
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 4: 17 patents in force now held by others · 5 lapsed for an unpaid fee · 6 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 abandoned · 11 no status recorded

Showing 1 to 10 of 14, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
17/961,478Topical Composition for Use in the Treatment of Inflammatory Bowel DiseaseOct 6, 2022Abandoned
17/798,056Mar 9, 2021No status recorded
17/798,052Mar 9, 2021No status recorded
17/774,432Nov 5, 2020No status recorded
17/798,050Oct 15, 2020No status recorded
17/762,017Sep 21, 2020No status recorded
17/761,920Sep 21, 2020No status recorded
17/761,843Sep 21, 2020No status recorded
17/620,648Bifidobacterium Bifidum Bacterial Strain, the Compositions Thereof and Related UsesJul 8, 2020Abandoned
17/611,880Jun 5, 2020No status recorded
10 of 14 applications shown.
Pro members see all 14 published applications.
Pro members: see all 14 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited